Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
Want to see PCRX full AI Analyst Report?
Earnings Data
Report Date
Aug 04, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.68Last Year’s EPS
0.74Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a predominately positive picture: the company reported solid top-line momentum across core products (EXPAREL, ZILRETTA, ioverao) with meaningful YoY growth, strengthened IP protection, expanded reimbursement coverage (110M+ covered lives), encouraging pipeline progress with near-term readouts, and healthy adjusted EBITDA and buyback activity. Near-term challenges include revenue mix impacts from a new GPO and winter storms, modest margin compression and elevated SG&A/R&D spending tied to strategic initiatives, and policy timing risk around NOPAIN’s scheduled 2027 expiration. On balance the positives — sustainable product growth, strengthened commercial and IP positions, active pipeline catalysts, and disciplined capital returns — outweigh the lowlights.Company Guidance
EXPAREL Net Sales and Volume Growth
EXPAREL net sales of $143.3M in Q1 2026 versus $136.5M in Q1 2025; reported volume growth of ~7% year-over-year, with continued momentum into 2026 driven by expanded reimbursement, a new product-specific J-code, non-opioid stewardship adoption, and protocol uptake.
ZILRETTA and ioverao Strong Performance
ZILRETTA Q1 sales of $26.8M, up 15% YoY ($23.3M in Q1 2025); ioverao Q1 sales of $6.2M, up 21% YoY ($5.1M in Q1 2025). Growth attributed to dedicated sales forces, expanded patient access programs, and partnerships (e.g., J&J MedTech for ZILRETTA).
Pipeline and Near‑Term Readouts
Key milestones: PCRX201 (HCAG gene therapy for knee OA) Part A fully enrolled with 49 patients and top-line results expected later this year; Part B planned to enroll ~90 additional patients midyear. ZILRETTA Phase 3 registrational study in shoulder OA enrollment concluded (top-line later this year). PCRX2002 expected to begin Phase 2 later this year; registrational study for ioverao in spasticity on track for year-end results.
Expanded IP Protection for EXPAREL
EXPAREL now has 21 Orange Book-listed patents across two families protecting the franchise, a significant improvement from a single patent previously litigated, supporting longer-term visibility and defense against generic challengers.
Commercial Access Expansion
Reimbursement progress: over 110 million covered lives with reimbursement for EXPAREL outside the surgical bundle (including NOPAIN-driven Medicare changes), and growing commercial payer recognition of EXPAREL value.
Financial Strength and Capital Returns
Adjusted EBITDA of approximately $40.2M in Q1; executed $50M in share repurchases in Q1 (retiring ~2.2M shares), reducing outstanding common shares to ~39.3M; $100M remaining under buyback authorization. Company reiterated full-year guidance: total revenues $745M–$770M and EXPAREL net sales $600M–$620M.
Manufacturing and Margin Efficiency
Non-GAAP consolidated gross margin of 80% in Q1 (vs. 81% prior year) benefiting from improved costs and efficiencies of enhanced larger-scale EXPAREL manufacturing and continuous improvement initiatives; PCRX201 highlighted as having favorable cost-of-goods potential due to local delivery and efficient manufacturing.
PCRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PCRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $25.49 | ― | ― |
Feb 26, 2026 | $22.59 | $21.91 | -3.01% |
Nov 06, 2025 | $21.10 | $22.05 | +4.50% |
Aug 05, 2025 | $22.54 | $22.40 | -0.62% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pacira Pharmaceuticals (PCRX) report earnings?
Pacira Pharmaceuticals (PCRX) is schdueled to report earning on Aug 04, 2026, Before Open (Confirmed).
What is Pacira Pharmaceuticals (PCRX) earnings time?
Pacira Pharmaceuticals (PCRX) earnings time is at Aug 04, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PCRX EPS forecast?
PCRX EPS forecast for the fiscal quarter 2026 (Q2) is 0.68.